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cDepartment of Inorganic and Analytical
Centre, University of Szeged, Dóm tér 7, H-6
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Hybrid systems are often endowed with completely different and improved properties compared to their
parent compounds. In order to extend the chemical space toward sterane-based molecular hybrids,
a number of estradiol-derived benzoxazol-2-ones with combined aromatic rings were synthesized via
the corresponding 2-aminophenol intermediates. 2-Aminoestradiol was first prepared from estrone by
a two-step nitration/reduction sequence under mild reaction conditions. Subsequent reductive
aminations with different arylaldehydes furnished secondary 2-aminoestradiol derivatives in good yields.
The proton dissociation processes of the aminoestradiols were investigated in aqueous solution by UV-
visible spectrophotometric titrations to reveal their actual chemical forms at physiological pH. The
determined pK1 and pK2 values are attributed to the
+NH3 or
+NH2R and OH moieties, and both varied
by the different R substituents of the amino group. Primary and secondary 2-aminoestradiols were next
reacted with carbonyldiimidazole as a phosgene equivalent to introduce a carbonyl group with
simultaneous ring-closure to give A-ring-fused oxazolone derivatives in high yields. The novel
aminoestradiols and benzoxazolones were subjected to in vitro cytotoxicity analysis and were found to
exert cancer cell specific activity.Introduction
Molecular hybridization is a very promising approach in drug
design and can offer therapeutic options for a wide variety of
diseases.1,2 The main goal of hybrid development is to enhance
or favourably modulate the pharmacokinetic and/or pharma-
codynamic properties of a molecule through the synergistic
effects of combined structural elements; although combating
multidrug resistance and minimizing unwanted side effects are
also important considerations. Occasionally, new, unpredict-
able bioactivities may arise which are different from those of the
individual molecules that constitute the hybrid compounds.3,4ity of Szeged, Dóm tér 8, H-6720 Szeged,
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tion (ESI) available. See DOI:
the Royal Society of ChemistryThanks to their attractive structural, physicochemical and
biological features, natural sex steroids are oen used to
construct molecular hybrids for anticancer indication,5–7 either
by covalent attachment to another pharmacophore directly8 or
via a spacer,9 or by integrating key functional elements to form
a new chemical entity.10 However, any residual hormonal effect
of the steroid moiety is undesirable in these cases, and should
be signicantly reduced or, preferably, eliminated during
hybrid formation.
For estrane-based hybrids, the best way to avoid hormonal
side effects is to modify the OH groups at positions C-3 and C-
17, which are primarily responsible for the hormone receptor
binding via H-bonding interactions.11 Decreased affinity to the
target protein, due to electronic and steric reasons, has also
been demonstrated for a number of 2-substituted estradiol
derivatives (e.g., 2-methoxyestradiol), which, however, are
effective in inhibiting the proliferation of various human cancer
cells.12–16 Although the cytotoxic effect of 2-nitroestradiol ob-
tained by direct nitration of estradiol was weaker than that of 2-
methoxyestradiol, the attachment of a piperidine or morpho-
line ring to the phenolic-O through a spacer led to particularly
potent cytotoxic compounds.17 Interestingly, there are very few
examples in the literature for the preparation of A-ring-modied
estrane-based derivatives containing a [2,3]-fused heterocyclicRSC Adv., 2021, 11, 13885–13896 | 13885
RSC Advances Papermoiety.18,19 Elimination of the phenolic OH group in parallel
with the substitution at C-2 makes it even more likely that the
compound will not be able to bind to hormone receptors, and
possibly other major bioactivities can predominate without
undesired side effects.
Since 2-aminophenols are valuable building blocks for many
biologically active compounds20 and can be used as starting
materials for the synthesis of pharmacologically important N,O-
heterocycles,21–23 our primary aim was to introduce an amino
substituent at the C-2 position of estradiol. In view of the high
reactivity of the phenolic A-ring of estrogens toward electro-
philes and the two available ortho positions (C-2 and C-4), the
regioselective introduction of a substituent into C-2 that can be
easily converted to an amino group is a challenging task.
Although C-2 attack is slightly favoured, in most of the cases,
e.g. during halogenation, nitration or formylation, mixtures of
mono- and disubstituted products – which are oen difficult to
separate – were usually obtained, and the yield of the 2-func-
tionalized derivative was only moderate.24 Accordingly, the rst
step of the seemingly simplest process involving nitration and
subsequent reduction for the synthesis of primary 2-amino
estradiol oen suffered from the above-mentioned
problems.25,26
When forming a 2-aminophenol moiety on estrogens, given
the high cost of sex hormones, it is desirable to develop
a process that consists of only few reaction steps and provides
the product in acceptable yield. Moreover, if the amino deriva-
tive is to be used as a starting material for the preparation
of N,O-heterocycles, it must be synthesized in a reproducible
manner in larger quantities. Although the task does not seem
difficult from an organic chemical point of view, it is no coin-
cidence that there are only few literature examples for the
preparation of 2-aminoestrone or 2-aminoestradiol, most of
which are based on a two-step procedure, i.e. nitration and
subsequent reduction aer separation of the mono- and dinitroFig. 1 Possible routes for the synthesis of 2-amino estrogens.
13886 | RSC Adv., 2021, 11, 13885–13896derivatives26–30 (Fig. 1B). All other synthetic methods, e.g. those
depicted in Fig. 1A31–36 and Fig. 1C,37,38 involve several steps and
require protection/deprotection of the phenolic OH group,
expensive reagents or harsh conditions, and suffer from selec-
tivity problems that ultimately lead to the nal product in lower
yields than route B.
In addition to studying a number of methods that may be
suitable for the most efficient and scalable access to 2-amino-
estradiol, our next goal was to further convert the compound to
secondary aminophenols by reductive amination. In order to
characterize the actual chemical forms (and charges) of the
novel compounds in solution focusing on physiological pH, and
to explore the effect of the various substituents on the aromatic
ring of the benzylaminomoiety in the case of secondary amines,
the proton dissociation constants (Ka) of the amphoteric ami-
nophenols were determined by UV-visible spectrophotometric
titrations. Finally, bifunctional derivatives were subjected to
CDI-induced ring-closure reactions with the simultaneous
incorporation of a carbonyl group from the reagent to furnish
various novel estradiol–benzoxazolone molecular hybrids. The
cytotoxicity of all synthesized derivatives was tested in vitro by
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay using human MCF-
7 breast, HeLa cervical as well as DU145 and PC-3 prostate
cancer cell lines, and simultaneously non-cancerous MRC-5
broblast cells. Based on the primary toxicity screen, ve
potent compounds were selected and subjected to further
experiments to obtain their IC50 values on different cell lines.Result and discussion
Synthetic studies
Based on the literature background, we selected the two-step
method for the preparation of 2-aminoestradiol; however,
both the nitration of estrone and the following reduction were© 2021 The Author(s). Published by the Royal Society of Chemistry
Paper RSC Advancesinvestigated separately. Since mononitration seemed unavoid-
able at both the C-2 and C-4 positions of the sterane core, we
tried to nd a proper experimental condition where at least
over-nitration and thus the formation of the dinitro product
could be eliminated. A number of literature procedures
describing the selective mononitration of phenol or estrone
either by using 65% (m/m) HNO3 29 or metal nitrates28 were tried
to be reproduced in different solvents (such as AcOH, dioxane,
EtOH, CH2Cl2 or CHCl3), however, signicant amount of 2,4-
dinitro derivative reducing the yield of the desired product, was
obtained in all cases. Furthermore, unreacted estrone remained
in the reaction mixtures when the nitrating agent was not used
in excess, which further complicated the separation and puri-
cation process.
Since the selective nitration of phenol and substituted
phenols to the corresponding mononitro compounds was re-
ported earlier under mild conditions in a liquid–liquid two-
phase system with diluted nitric acid (6% m/m) and in the
presence of tetrabutylammonium bromide as phase-transfer
catalyst,39 we tried to adapt this method on the substitution
reaction of estrone (1). However, given the poor solubility of
estrone relative to phenol in water-immiscible organic solvents,
a relatively large amount had to be used to prepare a homoge-
neous solution, so that the volume of water (added with
a diluted HNO3 solution) was signicantly smaller than that of
the organic phase. Therefore, a phase transfer catalyst was not
required even during the scale-up synthesis; the reaction pro-
ceeded with 1 equiv. of nitrating reagent in boiling CH2Cl2
under vigorous stirring for 1 h to give exclusively a ca. 1 : 1
mixture of 2- and 4-nitroestrone in 92% overall yield (Scheme 1).
The mononitro derivatives were easily separated by column
chromatography owing to their large polarity difference. First, 2-
nitroestrone (2) eluted from the column; its more apolar nature
is due to the intramolecular hydrogen bonding interaction
between the phenolic OH and the NO2 group. In contrast, the
more polar character of 4-nitroestrone (3) can be attributed to
the fact that due to its sterically hindered environment, the
nitro group twists out of the plane of the sterane skeleton,40
therefore, intramolecular interaction masking the polarity of
the functional groups cannot develop.
Although mononitration was not regioselective, both
successfully separated nitro compounds (2 and 3) subsequentlyScheme 1 Two-step synthesis of monoamino-estradiol regioisomers an
© 2021 The Author(s). Published by the Royal Society of Chemistryproved to be suitable, aer reduction, for the synthesis of A-ring
[2,3]-fused and [3,4]-fused 2-oxazolones.
As a continuation, conversion of 2 and 3 to aminoestradiols
was investigated. An insoluble red precipitate was formed as
a by-product when 2-nitrophenols (2 or 3) were reduced with
iron lings under classical Béchamp conditions, probably due
to metal complex formation, and then complex dissociation by
adding NaOH was also unsuccessful thanks to the high
susceptibility of sodium phenolates to oxidation. Therefore,
another hydrogenation method had to be found. In order to
avoid introducing ammable hydrogen into the reaction
mixture from a gas cylinder, hydrogen generated in situ from
NaBH4 in a protic solvent (MeOH) in the presence of Pd–C41,42
was used for catalytic reduction of 2 and 3 (Scheme 1). This
method was also suitable to reduce not only the NO2 but also
the 17-(C]O) group stereoselectively, thus resulting in 2- (4) or
4-aminoestradiol (6) in a single step with excellent isolated
yields. In view of the amphoteric character of the products,
adjustment of neutral pH during work-up was of crucial
importance.
In the following, unsubstituted (8a) and para-substituted
benzylamino estradiols (8b–h) were prepared from 4 with
benzaldehyde and its derivatives by reductive amination
(Table 1). Imine formation was performed in the presence of
a catalytic amount of AcOH and molecular sieves by boiling the
reactants in MeOH for 1 h. Secondary aminophenols (8a–h)
were obtained in good to excellent yields by reducing the
unstable imines in situ with NaBH4. With the only exception of
the p-nitro-substituted compound (8f), all derivatives were
found to be stable both in the solid state and in organic solvents
(Table 1).
Both the prepared primary (4 and 6) and secondary amines
(8a–h) were further converted to estradiol–benzoxazolone
hybrids by cyclization and incorporation of a carbonyl group
from the applied 1,1-carbonyldiimidazole (CDI) reagent in the
presence of triethylamine (TEA) as base by boiling in THF
(Scheme 1 and Table 1). The reactions provided the products (5,
7 and 9a–h) in good yield (67–94%) within 2 h.
The structures of all compounds prepared in our experi-
mental work were conrmed by 1H and 13C NMR spectroscopic
and high-resolution electrospray ionization mass spectrometry
(ESI-HRMS) methods. Due to the nature of the transformationsd their conversion to A-ring-fused 2-oxazolones.
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Table 1 Synthesis of secondary aminoestradiols by reductive amination and their conversion to A-ring-fused N-substituted 2-oxazolones
Entry R Aminoestradiol Yielda (%) Benzoxazolone Yielda (%)
1 H 8a 76 9a 69
2 F 8b 76 9b 76
3 Cl 8c 91 9c 94
4 Br 8d 75 9d 77
5 CN 8e 96 9e 92
6 NO2 8f 82
b 9f 92
7 CH3 8g 72 9g 78
8 OMe 8h 94 9h 90
a Aer purication by column chromatography. b Proved to be sensitive to oxidation even in the solid state.
Fig. 2 (a) UV-visible spectra recorded for 4 at various pH values. (b)
Concentration distribution curves calculated for 4 and the measured
absorbance values at 310 nm (C) with the fitted values (blue solid line).
{c¼ 50 mM; l¼ 2 cm; 30% (v/v) DMSO/H2O; T ¼ 25 C; I¼ 0.1 M (KCl)}.
RSC Advances Paperperformed, the range of 1H NMR spectra above chemical shi
values of 3 ppmwas informative; below 3 ppm, the signals of the
skeletal protons and the C-13 angular methyl group could be
observed. The most important difference between 2- and 4-
nitroestrone (2, 3) and 2- and 4-aminoestradiol (4, 6) derivatives
can be noticed in the aromatic range of the 1H NMR spectra. For
the 2,3-disubstituted compounds (2, 4), the C-1 and C-4 protons
give singlet signals, while the adjacent C-1 and C-2 protons of
the 3,4-disubstituted analogs (3, 6) appear as doublets with the
same coupling constant. In the spectra of the secondary ami-
nophenols (8), the appearance of the extra signals between 7
and 8 ppm as well as the presence of the benzyl-CH2 at 4.3 ppm
are indicative for the incorporation of the aromatic ring from
the arylaldehyde reagents and the success of the reductive
amination. As for the oxazolone (5, 7, 9) derivatives, the negative
carbon signal of the introduced C]O group can be seen at
around 154 ppm in the 13C NMR spectra (J-MOD), which indi-
cated the heterocyclization of the aminophenols upon treat-
ment with CDI.
Proton dissociation processes of primary and secondary
aminoestradiols
The methods (NMR, ESI-HRMS) used for the characterization of
2-aminoestradiols (4 and 8a–h) provide information about their
purity and chemical structure in the solid phase and in solution
of organic solvents. However, knowledge on their behaviour in
aqueous solution and proton dissociation is essential for
a deeper understanding of their pharmacological properties
and structure–activity relationships. Therefore, we aimed to
determine the proton dissociation constants (Ka) of the
compounds to predict their actual chemical forms at pH 7.4 in
solution, and to reveal the inuence of the various substituents.
The studied sterane-based derivatives (4 and 8a–h) have limited
solubility in pure water, thus UV-visible spectrophotometric
titrations were performed on samples containing 50 mM13888 | RSC Adv., 2021, 11, 13885–13896compound in a 30% (v/v) DMSO/H2O solvent mixture. However,
the halogen and CN substituents in 8b–e resulted in worse
solubility, and lower compound concentration (10 mM) had to
be applied to avoid the appearance of precipitate. Since 2-ami-
nophenol (2AP) and its derivatives can easily undergo oxidation,
especially in their completely deprotonated forms,43,44 a strong
argon ow was applied during the titrations to exclude the
oxygen. Deprotonation processes of 2AP as a simpler model© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 3 (a) UV-visible spectra recorded for 8a at various pH values.
Inserted figure shows the measured absorbance values at 312 nm (C)
with the fitted values (solid line) (b) concentration distribution curves
calculated for 8a. {c ¼ 50 mM; l ¼ 2 cm; 30% (v/v) DMSO/H2O; T ¼
25 C; I ¼ 0.1 M (KCl)}.
Paper RSC Advancescompound were also investigated for comparison. The studied
compounds displayed strong absorption bands in the UV region
mostly due to p–p* transitions of the benzene rings. Repre-
sentative UV-visible spectra recorded for 4 at various pH values
are shown in Fig. 2a. Two well-separated processes can be
observed upon increasing the pH; namely, the rst step is
accompanied by an increase of the absorbance and the lmax
from 282 nm to 296 nm in the pH range from 2 to 7, while the
second deprotonation step, taking place at pH > 9.5 results in
a further increase in the lmax (310 nm) with the appearance of
a novel band in the wavelength range 350–470 nm. As the
deprotonation steps are not overlapping, clear-cut isosbestic
points could be found at 284 nm and 302 nm in case of the H2L
+
# HL + H+ and HL # L + H+ equilibrium processes, respec-
tively, where L is the completely deprotonated form of the
compound. This nding also indicates that no disturbing
processes such as oxidation took place during the titration of 4
under the ow of the inert gas. Proton dissociation constants
(Ka) were determined by the deconvolution of the measured
spectra and are collected in Table 2.
Based on the determined pKa values, concentration distri-
bution curves were computed (Fig. 2b) showing the predomi-
nant formation of the HL species in the pH range ca. 6–9.5. The
pKa values were also determined for 2AP and sterane-based
compounds based on the recorded spectra (Table 2, see repre-
sentative spectra and concentration distribution curves for 8a in
Fig. 3). Notably, the spectra recorded for the compounds with
the methoxy (8h), nitrile (8e), chlorine (8c) and bromine
substituents (8d) showed a certain extent of oxidation in the
basic pH range (as no clear isosbestic point was found at pH >
10); therefore, the pK2 values could not be determined
accurately.
Similarly to the case of 2AP,45 the pK1 values are attributed to
the amino moiety (NH3
+ or NH2
+) in all cases, while the pK2
values belong to the phenolic OH group. Since the pK1 and pK2
values are in the range 3.85–4.82 and 10.34–11.1, respectively, it
can be concluded that all the studied compounds are in their
neutral HL form at the physiological pH, and become air
sensitive only in the basic pH range (pH > 9) when the depro-
tonation of the phenolic OH group starts.Table 2 Proton dissociation constants (pKa) of the compounds (cL ¼ 10 o












© 2021 The Author(s). Published by the Royal Society of ChemistryAs it is expected, the pKa values determined for 2AP in pure
water (pK1 ¼ 4.91 and pK2 ¼ 9.87 45) differ somewhat from those
obtained in this work using 30% (v/v) DMSO/H2O solvent
mixture. Namely, the pKa of the NH3
+ group is lower, while that
of the phenolic-OH is higher in the presence of the DMSO than
in pure water. DMSO has a lower charge neutralization
deprotonation/protonation processes are more favourable in
the more apolar medium. Comparing the pKa values to each
other (Table 2), it can be concluded that the incorporation of
2AP into the sterane core resulted in an increase in both of the
pKa values due to the electron-donating effect of the neigh-
bouring B-ring of the sterane core (c.f. 2AP and 4). Derivatization
on the amino group resulted in secondary amines, and the
introduction of the benzyl functional group led to lower pKar 50 mM) determined by UV-visible spectrophotometric titrations. {T ¼
pKa (NH
+
amino) pKa (OHphenolic) cL
4.41  0.02 10.36  0.02 50 mM
4.82  0.01 10.63  0.02 50 mM
4.58  0.03 10.44  0.04 50 mM
4.23  0.04 10.36  0.02 10 mM
4.34  0.05 10.8 10 mM
3.94  0.02 11.1 10 mM
3.85  0.01 11.0 10 mM
4.75  0.03 10.34  0.05 50 mM
4.76  0.03 10.6 50 mM
RSC Adv., 2021, 11, 13885–13896 | 13889
Table 3 IC50 (SD) values of some selected estrane-based derivatives
and of cisplatin assessed on non-cancerous MRC-5 cells as well as on




2 >2.5  1.35 1.1  1.01 —
5 >2.5  1.41 0.09  1.39 0.7  1.01
7 >2.5  1.02 1.2  1.01 —
8c >2.5  1.02 — 1.1  1.01
9b >2.5  1.09 — 1.2  1.01
Cisplatin 31.8  1.09 347.3  1.08 117.8  1.02
RSC Advances Papervalues (c.f. 4 and 8a). The pKa values of all the other derivatives
(8b–e, 8g and 8h) are compared to those of 8a as a reference
compound. The electron-donating methyl (8g) and methoxy
substituents (8h) slightly increased the pKa of the amino group,
while the electron-withdrawing CN (8e) and halo substituents
(8b–d) decreased it according to the expectations. Notably, the
largest effect was observed in the case of the nitrile and bromo
substituents. Differences were also observed in the case of the
pKa values of the phenolic OH group. This group is located
further away from the benzyl ring, and the inuence of
substituents on pK2 needs some explanations. Effect of the CH3,
MeO and F groups was negligible, while signicantly higher pK2
values were obtained in the case of the other substituents,
although these values are more questionable due to the recog-
nized oxidation process. Most probably, the substituent effect
can be realized via the possible N/OH hydrogen bond between
the deprotonated amino group and the phenolic OH, and the
electron-withdrawing groups might result in a stronger
hydrogen bond leading to the increase of the pK2 values.Pharmacological studies of the synthesized compounds
Cytotoxicity of all the synthesized derivatives was tested in vitro
on cancerous cell lines MCF-7, PC-3, DU145, and HeLa and also
on non-cancerous MRC-5 broblasts. For the preliminary
screen, compounds were applied in 1.5 mM concentration for
72 h, and a heat map (Fig. 4, ESI, Table S1‡) was constructed
with the mean cytotoxicity values obtained from three inde-
pendent experiments. The results of the screen indicated that at
1.5 mM concentration, all the compounds, except for 8a, 8e, 9a
and 9h induced cytotoxicity in at least one or in more cancerous
cells (PC-3, DU145, and HeLa), but not in non-cancerous MRC-5
broblasts, suggesting that most of the synthesized compounds
exhibit a cancer cell-selective toxic feature. Interestingly, none
of the compounds showed cytotoxicity on MCF-7 breast cancer
cells. These cancer cells lack caspase-3,46 a crucial cellularFig. 4 The primary cytotoxic effect of the synthesized aminoestradiols
and benzoxazolones on various human cancerous cell lines and on
non-cancerous MRC-5 fibroblasts shown on a heat map (c ¼ 1.5 mM;
72 h incubation time). Control represents the viability of untreated
cells.
13890 | RSC Adv., 2021, 11, 13885–13896enzyme required to orchestrate programmed cell death.47 The
observed ndings imply that the toxicity induced by these
compounds might depend on functional caspase-3, however,
further studies are required to prove this notion.
Based on the data of the overall toxicity screen, we selected
some derivatives that induced the strongest toxic effects in one
or more cancer cell lines. Therefore, we chose compounds 5, 8c
and 9b to be tested further on DU145, compounds 2, 5, and 7 for
a more profound examination on HeLa, and nally, all the
aforementioned molecules (namely 2, 5, 7, 8c and 9b) were
examined on MRC-5 cells to assess their IC50 values. Since none
of these molecules showed cytotoxicity in MCF-7 breast cancer
cells, and only two of them were slightly effective on PC-3
prostate cancer cells, these cell lines were omitted from
further analyses.
For IC50 determination, the selected steroids or cisplatin
(positive control) were applied at different concentrations on
the cell lines, and at the end of the treatments cell viability was
measured via MTT assay. Dose-response curves were tted on
the obtained viability data (ESI, Fig. S1‡), and subsequently the
corresponding IC50 values were calculated (Table 3).
In agreement with the preliminary screen, all the tested
compounds, notably, 2-nitroestrone (2), the A-ring-fused 2-
oxazolones (5, 7), the secondary aminoestradiol 8c and also the
A-ring-fused-N-substituted 2-oxazolone 9b were effective on
cancerous cells at several fold lower concentrations (Table 3,
Fig. S1 and S2‡) compared to positive control cisplatin.
Unlike the tested steroid derivatives, cisplatin did not show
any cancer cell specic cytotoxicity, which implies a potential
advantage of these compounds as candidates for future thera-
peutic developments. The most potent molecule on HeLa cells
proved to be the A-ring-fused 2-oxazolone (5), whereas the
secondary aminoestradiol 8c and the benzoxazolone 9b were
the most effective agents on DU145 prostate cancer cells despite
being ineffective on HeLa cells. It is noteworthy that compound
8c exerted the strongest effect also on the other prostate cancer
cell line PC-3.
Conclusions
In summary, we developed an efficient methodology for the
mononitration of estrone at C-2 and C-4 positions. Reduction of
nitroestrones by in situ generated hydrogen under catalytic
conditions resulted in 2- and 4-aminoestradiol derivatives in© 2021 The Author(s). Published by the Royal Society of Chemistry
Paper RSC Advancesa single step. Primary and secondary aminoestradiols, the latter
obtained by reductive amination of benzaldehyde and p-
substituted arylaldehydes with 2-aminoestradiol, were sub-
jected to cyclization with CDI to afford A-ring-integrated estra-
diol–benzoxazolone hybrids in good to excellent yields.
Compounds 4, 8a–h were characterized by two pKa values
that belong to the amino (pK1) and the phenolic-OH (pK2)
moieties, respectively. Based on the determined values (pK1 ¼
3.9–4.8; pK2 ¼ 10.3–11.1), all the studied compounds are
present in their neutral form in a wide pH range, including the
physiological pH. These aminophenol derivatives become air-
sensitive as the deprotonation of the OH functional group
starts, thus in the basic pH range (pH > 9). The substituents on
the benzyl function of the secondary amines (8) have an impact
on the proton dissociation processes mainly of the amino
group, namely, the electron-donating CH3 and MeO groups
increase pK1, while CN and the halogens decrease it.
Based on a preliminary cytotoxicity screen indicating
a possible cancer cell-selective pharmacological effect of the
synthesized compounds, the 5 most potent agents – A-ring-
fused 2-oxazolones (5, 7), the 2-nitroestrone (2), the secondary
aminoestradiol 8c and also the A-ring-fused-N-substituted 2-
oxazolone 9b – were selected for more thorough testing. The
chosen derivatives were effective at lower concentrations on
HeLa and DU145 cancerous cells than cisplatin, highlighting




Chemicals, reagents, and solvents were purchased from
commercial suppliers (Sigma-Aldrich and Alfa Aesar) and used
without further purication. Melting points (Mp) were deter-
mined on an SRS Optimelt digital apparatus and are uncor-
rected. The transformations were monitored by TLC using
0.25 mm thick Kieselgel-G plates (Si 254 F, Merck). The
compound spots were detected by spraying with 5% phospho-
molybdic acid in 50% aqueous phosphoric acid. Flash chro-
matographic purications were carried out on silica gel 60, 40–
63 mm (Merck). NMR spectra were recorded with a Bruker DRX
500 instrument at room temperature in CDCl3 or DMSO-d6
using residual solvent signals as an internal reference. Chem-
ical shis are reported in ppm (d scale), and coupling constants
(J) are given in Hz. Multiplicities of the 1H signals are indicated
as a singlet (s), a doublet (d), doublet of doublets (dd), doublet
of triplets (dt) a triplet (t), triplet of doublets (td), or a multiplet
(m). 13C NMR spectra are 1H-decoupled and the J-MOD pulse
sequence was used for multiplicity editing. In this spin-echo
type experiment, the signal intensity is modulated by the
different coupling constants J of carbons depending on the
number of attached protons. Both protonated and unproto-
nated carbons can be detected (CH3 and CH carbons appear as
positive signals, while CH2 and C carbons as negative signals).
ESI-HRMS spectra were recorded on a Q Exactive Plus hybrid
quadrupole-orbitrap mass spectrometer (Thermo Scientic)
equipped with a heated electrospray ionization (HESI-II) probe© 2021 The Author(s). Published by the Royal Society of Chemistrythat was used in positive and negative ion mode. Samples
introduced with FIA (ow injection analysis) method, eluent
stream (water, acetonitrile in 1 : 1 volume ratio with 0.1% for-
mic acid) was provided by a Waters Acquity I-class liquid
chromatograph (Waters).Synthetic procedures
Nitration of estrone (1). To a solution of estrone (1, 5.41 g, 20
mmol) in CH2Cl2 (540 mL), nitric acid (6% (m/m), 15.4 mL, 1
equiv.) was added dropwise and the reaction mixture was
heated at reux temperature for 1 h, aer which TLC moni-
toring indicated the completion of the reaction and the
formation of two new products (2 and 3). The solvent was
removed in vacuo, and the remaining crude product was puri-
ed by column chromatography on silica gel (eluent: EtOAc/
CH2Cl2 ¼ 2 : 98).
2-Nitroestra-1,3,5(10)-triene-17-one (2). Yield: 3.03mg (48%);
bright yellow crystals; Mp 258–260 C; ESI-HRMS: m/z 314.1394
[M], 314.1398 calcd for C18H21NO4;
1H NMR (500 MHz, CDCl3):
d 0.91 (3H, s, 18-CH3), 1.39–1.69 (6H, m), 1.96–2.10 (3H, m), 2.15
(1H, dt, J 18.9, 8.9), 2.18–2.27 (1H, m), 2.38–2.46 (1H, m), 2.51
(1H, m), 2.85–3.02 (2H, m, 6-H2), 6.86 (1H, d, J 1.1, 4-H), 7.97
(1H, d, J 1.5, 1-H), 10.40 (1H, s, 3-OH); 13C NMR (125 MHz,
CDCl3): d 13.9 (18-CH3), 21.7 (CH2), 25.8 (CH2), 26.0 (CH2), 29.7
(CH2), 31.4 (CH2), 35.9 (CH2), 37.8 (8-CH), 43.6 (9-CH), 47.9 (13-
C), 50.5 (14-CH), 119.1 (4-CH), 121.7 (1-CH), 131.9 (2-C), 133.2
(10-C), 148.9 (5-C), 153.0 (3-C), 220.3 (17-C).
4-Nitroestra-1,3,5(10)-triene-17-one (3). Yield: 2.86 g (45%);
yellowish white powder; Mp 165–166 C; ESI-HRMS: m/z
314.1394 [M], 314.1398 calcd for C18H21NO4;
1H NMR (500
MHz, DMSO-d6): d 0.83 (3H, s, 18-CH3), 1.28–1.45 (3H, m), 1.42–
1.62 (3H, m), 1.71–1.82 (1H, m), 1.95 (2H, m), 2.06 (1H, dt, J
18.9, 8.8), 2.19 (1H, td, J 10.4, 4.7), 2.28–2.39 (1H, m), 2.39–2.48
(1H, m), 2.61 (1H, m), 2.70 (1H, m), 6.86 (1H, d, J 8.6, 2-H), 7.30
(1H, d, J 8.7, 1-H), 10.45 (1H, s, 3-OH); 13C NMR (125 MHz,
DMSO-d6): d 13.4 (18-CH3), 20.9 (CH2), 23.4 (CH2), 24.8 (CH2),
25.4 (CH2), 31.1 (CH2), 35.2 (CH2), 36.9 (8-CH), 43.1 (9-CH), 47.1
(13-C), 49.2 (14-CH), 114.4 (2-CH), 127.8 (5-C), 127.8 (1-CH),
131.1 (10-C), 140.3 (4-C), 146.3 (3-C), 219.2 (17-C).
Reduction of nitroestrone derivatives. 2- (2) or 4-nitroestrone
(3) (1.89 g, 6 mmol) was dissolved in MeOH/THF ¼ 1 : 1 (100
mL) and cooled to 0 C, followed by the addition of 10% Pd–C
(200 mg). To this suspension, NaBH4 (0.91 g, 24 mmol, 4 equiv.)
was added in small portions. Aer 30 min, TLC indicated
complete conversion, so the solution was neutralized with
diluted HCl, ltered through a Cellite® pad for the removal of
the Pd–C catalyst, and the solvent was evaporated under
reduced pressure. To the crude product MeOH (20 mL) was
added, and the solution was poured onto ice-cold water. The
forming white precipitate was ltered off, washed with water,
and dried.
2-Aminoestra-1,3,5(10)-triene-3,17b-diol (4). Substrate: 2,
yield: 1.78 g, (97%, white solid); Mp 188–190 C, ESI-HRMS: m/z
288.1969 [M + H]+, 288.1958 calcd for C18H25NO2;
1H NMR (500
MHz, DMSO-d6): d 0.67 (3H, s, 18-CH3), 1.03–1.36 (6H, m), 1.38
(1H, m), 1.52–1.62 (1H, m), 1.74 (1H, m), 1.79–1.86 (1H, m),RSC Adv., 2021, 11, 13885–13896 | 13891
RSC Advances Paper1.83–1.93 (1H, m), 2.01 (1H, s), 2.13 (1H, dt, J 12.1, 3.3), 2.55 (1H,
dt, J 10.3, 5.1), 2.61 (1H, m), 3.52 (1H, td, J 8.5, 4.6, 17a-H), 4.15
(2H, s, 2-NH2), 4.39 (1H, d, J 4.8, 17-OH), 6.32 (1H, s, 1 H), 6.52
(1H, s, 4 H), 8.52 (1H, s, 3-OH); 13C NMR (125 MHz, DMSO-d6):
d 11.1 (18-CH3), 22.7 (CH2), 26.2 (CH2), 27.3 (CH2), 28.3 (CH2),
29.9 (CH2), 36.6 (CH2), 38.8 (8-CH), 42.7 (C-13), 43.7 (9-CH), 49.6
(14-CH), 80.0 (17-CH), 111.6 (4-CH), 114.4 (1-CH), 123.8 (5-C),
130.5 (2-C), 133.8 (10-C), 142.0 (3-C).
4-Aminoestra-1,3,5(10)-triene-3,17b-diol (6). Substrate: 3,
yield: 1.68 g, (92%, brownish solid); the product was subjected to
ring-closure directly aer formation without characterization.General procedure for the synthesis of secondary
aminoestradiols (8a–h)
To a solution of 2-aminoestradiol (4, 287 mg, 1 mmol) in MeOH
(5 mL), catalytic amount of AcOH and molecular sieves were
added, followed by the addition of (p-substituted) benzaldehyde
(1.1 equiv.). The mixture was kept at reux temperature for 1 h,
cooled to room temperature and reduced with NaBH 4 (76 mg, 2
equiv.). Aer complete conversion of the Schiff-base (30 min,
TLC), the reaction was quenched with water, MeOH was
removed, and the remaining residue was extracted with EtOAc
(3 5 mL). The combined organic phase was washed with water
and brine, dried over Na2SO4, and concentrated in vacuo. The
crude product was puried by column chromatography using
EtOAc/CH2Cl2 (5 : 95) as eluent.
2-(Benzylamino)estra-1,3,5(10)-triene-3,17b-diol (8a). The
synthesis was carried out according to the general procedure,
using benzaldehyde (110 mL, 117 mg). Yield: 286 mg (76%);
white solid; Mp 171–173 C; ESI-HRMS: m/z 378.2440 [M + H]+,
378.2428 calcd for C25H32NO2
+; 1H NMR (500 MHz, DMSO-d6):
d 0.63 (3H, s, 18-CH3), 0.99–1.29 (6H, m), 1.36 (1H, m), 1.55 (1H,
m), 1.75 (2H, m), 1.86 (1H, m), 1.97 (1H, td, J 10.7, 4.0), 2.04 (1H,
dt, J 10.7, 3.4), 2.55 (1H, dd, J 6.1, 2.1), 2.60 (1H, m), 3.49 (1H, td,
J 8.5, 4.5, 17a-H), 4.26 (2H, d, J 5.3, N–CH2), 4.38 (1H, d, J 4.8, 17-
OH), 4.85 (1H, t, J 6.2, –NH), 6.35 (2H, d, J 5.0, 1 H, 4 H), 7.18–
7.25 (1H, m, 40-H), 7.27–7.37 (4H, m, 20-H, 30-H, 50-H, 60-H), 8.86
(1H, s, 3-OH); 13C NMR (125 MHz, DMSO-d6): d 11.1 (18-CH3),
22.7 (CH2), 26.0 (CH2), 27.2 (CH2), 28.3 (CH2), 29.9 (CH2), 36.6
(CH2), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 47.0 (N–CH2), 49.5
(14-CH), 80.0 (17-CH), 107.5 (4-CH), 113.7 (1-CH), 123.1 (5-C),
126.4 (40-C), 127.1 (20-CH and 60-CH), 128.1 (30-CH and 50-CH),
130.3 (10-C), 134.8 (2-C), 140.7 (10-C), 142.1 (3-C).
2-(40-Fluorobenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8b). The synthesis was carried out according to the general
procedure, using p-urobenzaldehyde (118 mL, 137 mg). Yield:
301 mg (76%); orange solid; Mp 163–165 C; ESI-MS: m/z
396.2341 [M + H]+, 396.2333 calcd for C25H31FNO2
+; 1H NMR
(500 MHz, DMSO-d6): d 0.63 (3H, s, 18-CH3), 1.01–1.27 (6H, m),
1.31–1.42 (1H, m), 1.55 (1H, m), 1.69–1.92 (3H, m), 1.97 (1H, td,
J 10.3, 3.6), 2.04 (1H, dd, J 12.8, 4.1), 2.52–2.64 (2H, m), 3.49 (1H,
td, J 8.5, 4.7, 17a-H), 4.22–4.27 (2H,m, N–CH2), 4.38 (1H, d, J 4.8,
17-OH), 4.90 (1H, s, –NH), 6.33 (2H, d, J 7.5, 1-H and 4-H), 7.11
(2H, t, J 8.9, 7.6, 30-H and 50-H), 7.37 (2H, dd, J 8.5, 20-H and 60-
H), 8.85 (1H, s, 3-OH); 13C NMR (125 MHz, DMSO-d6): d 11.1 (18-
CH3), 22.7 (CH2), 26.0 (CH2), 27.2 (CH2), 28.3 (CH2), 29.9 (CH2),13892 | RSC Adv., 2021, 11, 13885–1389636.6 (CH2), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.2 (N–CH2),
49.5 (14-CH), 80.0 (17-CH), 107.6 (1-CH), 113.7 (4-CH), 114.7,
114.8, 123.2 (5-C), 128.9 (CH), 128.9 (CH), 130.3 (10-C), 134.6 (2-
C), 136.8, 136.9, 142.1 (3-C), 160.0, 161.9.
2-(40-Chlorobenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8c). The synthesis was carried out according to the general
procedure, using p-chlorobenzaldehyde (154 mg). Yield: 376 mg
(91%); yellowish white solid; Mp 180–183 C; ESI-HRMS: m/z
412.2049 [M + H]+, 412.2038 calcd for C25H31ClNO2
+; 1H NMR
(500 MHz, DMSO-d6): d 0.62 (3H, s, 18-CH3), 1.00–1.28 (6H, m),
1.30–1.41 (1H, m), 1.54 (1H, m), 1.67–1.74 (1H, m), 1.74–1.80
(1H, m), 1.86 (1H, m), 1.91–2.06 (2H, m), 2.51–2.65 (2H, m), 3.48
(1H, td, J 8.5, 4.7, 17a-H), 4.25 (2H, d, J 5.7, N–CH2), 4.43 (1H, d, J
4.8, 17-OH), 5.02 (1H, t, J 6.3, –NH), 6.28 (1H, s, 1 H), 6.33 (1H, s,
4 H), 7.35 (4H, s, 20-H, 30-H, 50-H and 60-H), 8.92 (1H, s, 3-OH);
13C NMR (125 MHz, DMSO-d6): d 11.2 (18-CH3), 22.7 (CH2), 26.1
(CH2), 27.2 (CH2), 28.4 (CH2), 29.9 (CH2), 36.6 (CH2), 38.8 (8-
CH), 42.8 (13-C), 43.9 (9-CH), 46.1 (N–CH2), 49.5 (14-CH), 80.0
(17-CH), 107.5 (1-CH), 113.7 (4-CH), 123.3 (5-C), 128.1 (30-CH
and 50-CH), 128.9 (20-CH and 60-CH), 130.3 (40-C), 130.9 (10-C),
134.5 (2-C), 140.0 (10-C), 142.2 (3-C).
2-(40-Bromobenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8d). The synthesis was carried out according to the general
procedure, using p-bromobenzaldehyde (204 mg). Yield: 342 mg
(75%); white solid; Mp 172–175 C; ESI-MS: m/z 456.1542 [M +
H]+, 456.1533 calcd for C25H31BrNO2
+; 1H NMR (500 MHz,
DMSO-d6): d 0.63 (3H, s, 18-CH3), 1.00–1.09 (1H, m), 1.11–1.27
(5H, m), 1.36 (1H, m), 1.55 (1H, m), 1.68–1.78 (1H, m), 1.75–1.81
(1H, m), 1.86 (1H, m), 1.92–2.06 (2H, m), 2.52–2.64 (2H, m), 3.49
(1H, td, J 8.5, 4.8, 17a-H), 4.24 (2H, d, J 5.5, N–CH2), 4.38 (1H, d, J
4.8, 17-OH), 4.98 (1H, t, J 6.4, –NH), 6.29 (1H, s, 1-H), 6.34 (1H, s,
4-H), 7.30 (2H, d, J 8.3, 20-H and 60-H), 7.48 (2H, d, J 8.3, 30-H and
50-H), 8.86 (1H, s, 3-OH); 13C NMR (125 MHz, DMSO-d6): d 11.1
(18-CH3), 22.7 (CH2), 26.0 (CH2), 27.1 (CH2), 28.3 (CH2), 29.9
(CH2), 36.6 (CH2), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.2 (N–
CH2), 49.5 (14-CH), 80.0 (17-CH), 107.5 (1-CH), 113.7 (4-CH),
119.2 (40-C), 123.3 (5 C), 129.3 (20-CH and 60-CH), 130.3 (10 C),
130.9 (30-CH and 50-CH), 134.5 (2-C), 140.4 (3-C), 142.2 (10-C).
2-(40-Cyanobenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8e). The synthesis was carried out according to the general
procedure, using p-cyanobenzaldehyde (144 mg). Yield: 386 mg
(96%); white solid; Mp 184–187 C; ESI-HRMS: m/z 403.2391 [M
+ H]+, 403.2380 calcd for C26H31N2O2
+; 1H NMR (500 MHz,
DMSO-d6): d 0.61 (3H, s, 18-CH3), 0.99–1.35 (7H, m), 1.32–1.40
(1H, m), 1.54 (1H, m), 1.67–1.78 (1H, m), 1.85 (1H, m), 1.89–2.04
(2H, m), 2.51–2.64 (2H, m), 3.48 (1H, td, J 8.5, 4.7, 17a-H), 4.37
(2H, d, J 6.0, N–CH2), 4.42 (1H, d, J 4.8, 17-OH), 5.21 (1H, t, J 6.4,
–NH), 6.21 (1H, s, 1-H), 6.34 (1H, s, 4-H), 7.52 (2H, d, J 8.0, 20-H
and 60-H), 7.76 (2H, d, J 8.3, 30-H and 50-H), 8.96 (1H, s, 3-OH);
13C NMR (125 MHz, DMSO-d6): d 11.2 (18-CH3), 22.7 (CH2), 26.0
(CH2), 27.2 (CH2), 28.4 (CH2), 29.9 (CH2), 36.6 (CH2), 38.8 (8-
CH), 42.7 (13-C), 43.8 (9-CH), 46.4 (N–CH2), 49.5 (14-CH), 80.0
(17-CH), 107.5 (1-CH), 109.1 (40-C), 113.8 (4-CH), 119.0 (40-CN),
123.4 (5-C), 127.9 (20-CH and 60-CH), 130.3 (10-C), 132.1 (30-CH
and 50-CH), 134.3 (2-C), 142.3 (3-C), 147.4 (10-C).
2-(40-Nitrobenzylamino)estra-1,3,5(10)-triene-3,17b-diol (8f).
The synthesis was carried out according to the general© 2021 The Author(s). Published by the Royal Society of Chemistry
Paper RSC Advancesprocedure, using p-nitrobenzaldehyde (166 mg). Yield: 346 mg
(82%); yellow solid. Due to stability issues it was immediately
converted into 9f without purication.
2-(40-Methylbenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8g). The synthesis was carried out according to the general
procedure, using p-tolualdehyde (132 mg). Yield: 346 mg (72%);
white solid; Mp 151–153 C; ESI-HRMS: m/z 392.2596 [M + H]+,
392.2584 calcd for C26H34NO2
+; 1H NMR (500 MHz, DMSO-d6):
d 0.64 (3H, s, 18-CH3), 1.06–1.24 (6H, m), 1.31–1.42 (1H, m), 1.55
(1H, m), 1.69–1.76 (1H, m), 1.79 (1H, dt, J 12.3, 3.1), 1.87 (1H,
m), 1.93–2.02 (1H, m), 2.04–2.11 (1H, m), 2.27 (3H, s), 2.47–2.66
(2H, m), 3.50 (1H, td, J 8.5, 4.3, 17a-H), 4.20 (2H, s, N–CH2), 4.38
(1H, d, J 4.8, –NH), 4.77 (1H, s, 17-OH), 6.33 (1H, s, 1-H), 6.37
(1H, s, 4-H), 7.11 (2H, d, J 7.8, 30-H and 50-H), 7.23 (2H, d, J 8.0,
20-H and 60-H), 8.83 (1H, s, 3-OH); 13C NMR (125 MHz, DMSO-
d6): d 11.1 (18-CH3), 20.5 (CH2), 22.7 (CH2), 26.1 (CH2), 27.2
(CH2), 28.3 (CH2), 29.9 (CH2), 36.6 (CH2), 38.8 (8-CH), 42.7 (13-
C), 43.8 (9-CH), 46.8 (N–CH2), 49.5 (14-CH), 80.0 (17-CH), 107.5
(1-CH), 113.6 (4-CH), 123.1 (40-C), 127.1 (30-CH and 50-CH), 128.6
(20-CH and 60-CH), 130.3 (5-C), 134.80 (10-C), 135.4 (10-C), 137.5
(2-C), 142.1 (3-C).
2-(40-Methoxybenzylamino)estra-1,3,5(10)-triene-3,17b-diol
(8h). The synthesis was carried out according to the general
procedure, using p-anisaldehyde (134 mL, 150 mg). Yield:
384 mg (94%); white solid; Mp 135137 C; ESI-HRMS: m/z
408.2551 [M + H]+, 408.2533 calcd for C26H34NO3
+; 1H NMR (500
MHz, DMSO-d6): d 0.64 (3H, s, 18-CH3), 0.99–1.28 (6H, m), 1.36
(1H, m), 1.50–1.61 (1H, m), 1.68–1.92 (3H, m), 1.98 (1H, td, J
10.8, 4.0), 2.05–2.12 (1H, m), 2.57 (2H, m), 3.49 (1H, td, J 8.5, 4.7,
17a-H), 3.72 (3H, s, 40-OMe), 4.17 (2H, d, J 6.0, N–CH2), 4.43 (1H,
d, J 5.1, –NH), 4.75 (1H, t, J 6.2, 17-OH), 6.32 (1H, s, 1-H), 6.36
(1H, s, 4-H), 6.83–6.90 (2H, m, 30-H and 50-H), 7.23–7.28 (2H, m,
20-H and 60-H), 8.88 (1H, s, 3-OH); 13C NMR (125 MHz, DMSO-
d6): d 11.2 (18-CH3), 22.8 (CH2), 26.1 (CH2), 27.3 (CH2), 28.4
(CH2), 29.9 (CH2), 36.7 (CH2), 38.8 (8-CH), 42.8 (13-C), 43.9 (9-
CH), 46.5 (N–CH2), 49.5 (14-CH), 55.0 (40-OMe), 80.0 (17-CH),
107.6 (CH), 113.6 (30-CH and 50-CH), 123.1 (5-C), 128.4 (20-CH
and 60-CH), 130.3 (10-C), 132.5 (10-C), 134.8 (2-C), 142.2 (3-C),
158.0 (40-C).General procedure for the synthesis of oxazolone hybrids (5, 7
and 9a–h)
The primary (4 or 6) or secondary amine (8a–h) (0.5 mmol) was
dissolved in THF/CH2Cl2 ¼ 1 : 4 (5 mL), CDI (89 mg, 1.1 equiv.)
and TEA (140 mL, 1 mmol, 2 eq.) were added and the mixture
was kept at reux temperature for 2 h. The solvent was removed
under reduced pressure, the crude product was suspended in
water (5 mL), acidied with diluted HCl and extracted with
EtOAc (3  5 mL). The combined organic phase was washed
with water and brine, dried over anhydrous Na2SO4 and
concentrated in vacuo. The product was puried by column
chromatography.
Oxazolo[40,50:2,3]estra-1,3,5(10)-triene-17b-ol-20-one (5). Sub-
strate: 4 (144 mg); eluent: EtOAc/CH2Cl2 ¼ 50 : 50; yield: 120 mg
(76%); white powder; Mp 280–282 C; ESI-HRMS: m/z 314.1761
[M + H]+, 314.1751 calcd for C19H24NO3
+; 1H NMR (500 MHz,© 2021 The Author(s). Published by the Royal Society of ChemistryDMSO-d6): d 0.67 (3H, s), 1.06–1.45 (7H, m), 1.58 (1H, m), 1.79 (1H,
m), 1.88 (2H, m), 2.16 (1H, td, J 10.9, 4.2), 2.23 (1H, dt, J 12.9, 3.6),
2.80 (2H, dt, J 8.1, 4.1, 6-H2), 3.52 (1H, t, J 8.5, 17a-H), 4.45 (1H, s,
17-OH), 6.92 (2H, d, J 7.4, 1-H and 4 H), 11.32 (1H, s, NH).13C NMR
(125 MHz, DMSO-d6): d 11.1 (18-CH3), 22.7 (CH2), 26.1 (CH2), 26.6
(CH2), 29.0 (CH2), 29.8 (CH2), 36.5 (CH2), 38.2 (8-CH), 42.7 (13-C),
43.8 (9-CH), 49.6 (14-CH), 79.9 (17-CH), 106.2 (CH), 109.1 (CH),
128.2, 130.0, 135.6, 141.5, 154.6 (20-C).
Oxazolo[40,50:4,3]estra-1,3,5(10)-triene-17b-ol-20-one (7).
Substrate: 6 (144 mg); eluent: EtOAc/CH2Cl2 ¼ 50 : 50; yield:
105 mg (67%); white powder; Mp 258–260 C; ESI-HRMS: m/z
314.1757 [M + H]+, 314.1751 calcd for C19H24NO3
+; 1H NMR (500
MHz, DMSO-d6): d 0.67 (3H, s, 18-CH3), 1.07–1.44 (7H, m), 1.60
(1H, m), 1.88 (3H, m), 2.17 (1H, td, J 11.1, 4.3), 2.29 (1H, m),
2.59–2.70 (1H, m), 2.73–2.81 (1H, m), 3.53 (1H, td, J 8.5, 4.3, 17a-
H), 4.43 (1H, d, J 4.8, 17-OH), 7.00 (2H, s, 1-H and 4-H), 11.44
(1H, s, NH); 13C NMR (125 MHz, DMSO-d6): d 11.1 (18-CH3), 22.7
(CH2), 24.1 (CH2), 25.8 (CH2), 26.2 (CH2), 29.8 (CH2), 36.5 (CH2),
38.0 (8-CH), 42.6 (13-C), 43.6 (9-CH), 49.4 (14-CH), 79.9 (17-CH),
106.3 (2-CH), 118.3 (1-CH), 119.1 (5-C), 128.4 (4-C), 135.7 (3-C),
140.8 (10-C), 154.9 (20-C).
30-Benzyloxazolo[40,50:2,3]estra-1,3,5(10)-triene-17b-ol-20-one
(9a). Substrate: 8a (189 mg); eluent: EtOAc/CH2Cl2 ¼ 5 : 95;
yield: 139 mg (69%); white powder; Mp 148–150 C; ESI-HRMS:
m/z 404.2228 [M + H]+, 404.2220 calcd for C26H30NO3
+; 1H NMR
(500 MHz, CDCl3): d 0.77 (3H, s), 1.17 (1H, m), 1.23–1.54 (7H,
m), 1.70 (1H, m), 1.88 (1H, m), 1.94 (1H, m), 2.06–2.23 (3H, m),
2.79–2.94 (2H, m), 3.72 (1H, t, J 8.5, 17a-H), 4.90–5.03 (2H, m, N–
CH2), 6.75 (1H, s, 1-H), 6.91 (1H, s, 4-H), 7.31 (1H, dt, 400-CH),
7,31–7.39 (4H, m, 200-H, 300-H, 500-H and 600-H); 13C NMR (125
MHz, CDCl3): d 11.2 (18-CH3), 23.3 (CH2), 26.7 (CH2), 27.2 (CH2),
29.85 (CH2), 30.8 (CH2), 36.8 (CH2), 38.7 (8-CH), 43.3 (13-C), 44.4
(9-CH), 46.2 (N–CH2), 50.3 (14-CH), 81.9 (17-CH), 105.9 (4-CH),
110.1 (1-CH), 127.8 (300-CH and 500-CH), 128.3 (400-CH), 129.1 (100-
C), 129.1 (200-CH and 600-CH), 131.6 (2-C), 135.2 (5-C), 136.4 (10-
C), 141.2 (3-C), 155.3 (20-C).
30-(400-Fluorobenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9b). Substrate: 8b (198 mg); eluent: EtOAc/CH2Cl2
¼ 5 : 95; yield: 160 mg (76%); white powder; Mp 146–148 C;
ESI-HRMS: m/z 422.2136 [M + H]+, 422.2126 calcd for
C26H29FNO3
+; 1H NMR (500 MHz, CDCl3): d 0.77 (3H, s, 18-CH3),
1.13–1.75 (9H, m), 1.88 (1H, m), 1.96 (1H, dt, J 12.2, 2.9), 2.07–
2.24 (3H, m), 2.80–2.94 (2H, m), 3.73 (1H, t, J 8.5, 17a-H), 4.88–
4.99 (2H, m, N–CH2), 6.74 (1H, s, 1-H), 6.91 (1H, s, 4-H), 7.04
(2H, td, J 8.5, 1.4), 7.29–7.38 (2H, m); 13C NMR (125 MHz,
CDCl3): d 11.2 (18-CH3), 23.3 (CH2), 26.7 (CH2), 27.2 (CH2), 29.8
(CH2), 30.8 (CH2), 36.8 (CH2), 38.7 (8-CH), 43.3 (13-C), 44.4 (9-
CH), 45.4 (N–CH2), 50.3 (14-CH), 81.9 (17-CH), 105.7 (1-CH),
110.3 (4-CH), 116.0, 116.2, 128.8 (2-C), 129.5, 129.6, 131.0,
131.00, 131.8 (5-C), 136.4, 141.1, 155.2 (20-C), 161.7, 163.7.
30-(400-Chlorobenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9c). Substrate: 8c (206 mg); eluent: EtOAc/CH2Cl2
¼ 5 : 95; yield: 205 mg (94%); white powder; Mp 128–130 C;
ESI-HRMS: m/z 438.1840 [M + H]+, 438.1830 calcd for
C26H29ClNO3
+; 1H NMR (500 MHz, DMSO-d6): d 0.65 (3H, s, 18-
CH3), 1.05–1.43 (7H, m), 1.57 (1H, m), 1.78 (1H, m), 1.87 (2H,
m), 2.14 (1H, td, J 11.0, 4.2), 2.28 (1H, m), 2.77–2.83 (2H, m),RSC Adv., 2021, 11, 13885–13896 | 13893
RSC Advances Paper3.52 (1H, td, J 8.5, 4.9, 17a-H), 4.47 (1H, d, J 4.8, 17-OH), 5.02
(2H, s, N–CH2), 7.01 (1H, s, 4-H), 7.13 (1H, s, 1-H), 7.36–7.45 (4H,
m, 200-H, 300-H, 500-H and 600-H); 13C NMR (125 MHz, DMSO-d6):
d 11.2 (18-CH3), 22.7 (CH2), 26.1 (CH2), 26.6 (CH2), 29.1 (CH2),
29.9 (CH2), 36.5 (CH2), 38.2 (8-CH), 42.7 (13-C), 44.0 (over-
lapping, 9-CH and N–CH2), 49.5 (14-CH), 79.9 (17-CH), 106.2 (1-
CH), 109.5 (4-CH), 128.6 (2 C), 128.7 (300-CH and 500-CH), 129.4
(200-CH and 600-CH), 130.9 (400-C), 132.4 (5-C), 134.9 (100-C), 136.0
(10-C), 140.2 (3-C), 154.1 (20-C).
30-(400-Bromobenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9d). Substrate: 8d (228 mg); eluent: EtOAc/CH2Cl2
¼ 5 : 95; yield: 186 mg (77%); white powder; Mp 159–161 C;
ESI-HRMS: m/z 482.1335 [M + H]+, 482.1325 calcd for
C26H29BrNO3
+; 1H NMR (500 MHz, CDCl3): d 0.77 (3H, s, 18-
CH3), 1.13–1.54 (8H, m), 1.70 (1H, m), 1.88 (1H, m), 1.96 (1H,
m), 2.07–2.24 (3H, m), 2.80–2.94 (2H, m), 3.73 (1H, t, J 8.5, 17a-
H), 4.85–4.98 (2H, m), 6.72 (1H, s, 4 H), 6.92 (1H, s, 1-H), 7.22
(2H, s, J 8.4, 200-H and 600-H), 7.48 (2H, d, J 8.4, 300-H and 500-H);
13C NMR (125 MHz, CDCl3): d 11.2 (18-CH3), 23.3 (CH2), 26.7
(CH2), 27.2 (CH2), 29.9 (CH2), 30.8 (CH2), 36.8 (CH2), 38.6 (8-
CH), 43.3 (13-C), 44.4 (9-CH), 45.5 (N–CH2), 50.3 (14-CH), 81.9
(17-CH), 105.6 (1-CH), 110.3 (4-CH), 122.4 (400-C), 128.8 (2-C),
129.4 (200-CH and 600-CH), 131.9 (5-C), 132.3 (300-CH and 500-CH),
134.2 (100-C), 136.5 (10-C), 141.1 (3-C), 155.2 (20-C).
30-(400-Cyanobenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9e). Substrate: 8e (201 mg); eluent: EtOAc/CH2Cl2
¼ 10 : 90; yield: 197 mg (92%); white powder; Mp 134–137 C;
ESI-HRMS: m/z 429.2181 [M + H]+, 429.2173 calcd for
C27H29N2O3
+; 1H NMR (500 MHz, DMSO-d6): d 0.65 (3H, s, 18-
CH3), 1.04–1.43 (7H, m), 1.57 (1H, m), 1.74–1.93 (3H, m), 2.15
(1H, td, J 10.9, 4.0), 2.23–2.31 (1H, m), 2.81 (2H, dd, J 8.0, 3.9),
3.52 (1H, td, J 8.5, 4.8 17a-H), 4.47 (1H, d, J 4.8, 17-OH), 5.14
(2H, s, N–CH2), 7.04 (1H, s, 4-H), 7.15 (1H, s, 1-H), 7.53 (2H, d, J
8.3, 200-H and 600-H), 7.83 (2H, d, J 8.3, 300-H and 500-H); 13C NMR
(125 MHz, DMSO-d6): d 11.2 (18-CH3), 22.7 (CH2), 26.2 (CH2),
26.6 (CH2), 29.1 (CH2), 29.9 (CH2), 36.4 (CH2), 38.2 (8-CH), 42.7
(13-C), 44.0 (9-CH), 44.3 (N–CH2), 49.5 (14-CH), 79.9 (17-CH),
106.1 (1-CH), 109.5 (4-CH), 110.5 (400-CN), 118.5 (400-C), 128.2 (200-
CH and 600-CH), 128.6 (2-C), 131.0 (5-C), 132.6 (300-CH and 500-
CH), 136.1 (10-C), 140.2 (3-C), 141.5 (100-C), 154.1 (20-C).
30-(400-Nitrobenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9f). Substrate: 8f (211 mg); eluent: EtOAc/CH2Cl2 ¼
5 : 95; yield: 206 mg (92%); yellowish white powder; Mp 168–
170 C; ESI-HRMS: m/z 449.2082 [M + H]+, 449.2071 calcd for
C26H29N2O5
+; 1HNMR (500MHz, DMSO-d6): d 0.65 (3H, s, 18-CH3),
1.06–1.43 (7H, m), 1.58 (1H, m), 1.74–1.93 (3H, m), 2.15 (1H, td, J
10.9, 3.9), 2.24–2.32 (1H, m), 2.81 (2H, dd, J 8.1, 3.9), 3.51 (1H, td, J
8.5, 4.9, 17a-H), 4.47 (1H, d, J 4.8, 17-OH), 5.20 (2H, s, N–CH2), 7.05
(1H, s, 4-H), 7.17 (1H, s, 1-H), 7.60 (2H, d, J 8.8, 200-H and 600-H), 8.22
(2H, d, J 8.8, 300-H and 500-H); 13C NMR (125 MHz, DMSO-d6): d 11.2
(18-CH3), 22.7 (CH2), 26.2 (CH2), 26.6 (CH2), 29.1 (CH2), 29.9 (CH2),
36.4 (CH2), 38.2 (8-CH), 42.7 (13-C), 44.0 (9-CH), 44.1 (N–CH2), 49.5
(14-CH), 79.9 (17-CH), 106.2 (1-CH), 109.6 (4-CH), 123.8 (300-CH and
500-CH), 128.5 (200-CH and 600-CH), 128.6 (2-C), 131.1 (5-C), 136.2 (10-
C), 140.2 (3-C), 143.6 (100-C), 147.0 (400-C), 154.1 (20-C).
30-(400-Methylbenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9g). Substrate: 8g (196 mg); eluent: EtOAc/13894 | RSC Adv., 2021, 11, 13885–13896CH2Cl2 ¼ 5 : 95; yield: 163 mg (78%); white powder; Mp 129–
131 C; ESI-HRMS: m/z 418.2385 [M + H]+, 418.2377 calcd for
C27H32NO3
+; 1H NMR (500 MHz, DMSO-d6): d 0.66 (3H, s, 18-CH3),
1.04–1.47 (7H, m), 1.58 (1H, m), 1.69–1.82 (1H, m), 1.87 (2H, m),
2.15 (1H, td, J 11.2, 10.7, 4.0), 2.26 (4H,m), 2.80 (2H, dt, J 8.4, 3.6, 6-
H2), 3.52 (1H, td, J 8.5, 4.9, 17a-H), 4.42 (1H, d, J 4.8, 17-OH), 4.96
(2H, s, N–CH2), 7.00 (1H, s, 4-H), 7.09 (1H, s, 1-H), 7.16 (2H, d, J 7.8,
300-H and 500-H), 7.25 (2H, d, J 8.0, 200-H and 600-H); 13C NMR (125
MHz, DMSO-d6): d 11.1 (18-CH3), 20.5 (CH2), 22.6 (CH2), 26.1
(CH2), 26.5 (CH2), 29.0 (CH2), 29.8 (CH2), 36.4 (CH2), 38.1 (8-CH),
42.6 (13 C), 43.9 (9-CH), 44.5 (N–CH2), 49.5 (14-CH), 79.9 (17-CH),
106.1 (1-CH), 109.3 (4-CH), 127.4 (200-CH and 600-CH), 128.6 (2 C),
129.1 (300-CH and 500-CH), 130.7 (100-C), 132.7 (5 C), 135.9 (400-C),
136.9 (10-C), 140.1 (3-C), 154.1 (20-C).
30-(400-Methoxybenzyl)oxazolo[40,50:2,3]estra-1,3,5(10)-triene-
17b-ol-20-one (9h). Substrate: 8h (204mg); eluent: EtOAc/CH2Cl2
¼ 2 : 98; yield: 195 mg (90%); white powder; Mp 136–138 C;
ESI-MS: m/z 434.2335 [M + H]+, 434.2326 calcd for C27H32NO4
+;
1H NMR (500 MHz, DMSO-d6): d 0.66 (3H, s, 18-CH3), 1.10–1.43
(7H, m), 1.57 (1H, m), 1.78 (1H, m), 1.87 (2H, m), 2.15 (1H, td, J
10.9, 4.0), 2.25–2.33 (1H, m), 2.79 (2H, dt, J 8.4, 3.4), 3.52 (1H, td,
J 8.5, 4.7, 17a-H), 3.72 (3H, s, 400-OMe), 4.48 (1H, d, J 4.8, 17-OH),
4.94 (2H, s, N–CH2), 6.91 (2H, d, J 8.6, 300-H and 500-H), 7.00
(1H, s, 4-H), 7.12 (1H, s, 1-H), 7.32 (2H, d, J 8.6, 200-H and 600-H);
13C NMR (125 MHz, DMSO-d6): d 11.2 (18-CH3), 22.7 (CH2), 26.2
(CH2), 26.6 (CH2), 29.1 (CH2), 29.9 (CH2), 36.5 (CH2), 38.2 (8-
CH), 42.7 (13-C), 44.0 (9-CH), 44.2 (N–CH2), 49.5 (14-CH), 55.1
(400-OMe), 79.9 (17-CH), 106.3 (1-CH), 109.4 (4-CH), 114.1 (300-CH
and 500-CH), 127.8 (100-C), 128.6 (2 C), 129.0 (200-CH and 600-CH),
130.7 (5-C), 135.9 (10-C), 140.1 (3-C), 154.1 (20-C), 158.9 (400-C).
UV-visible spectrophotometric titrations
Stock solutions of tested compounds were prepared in DMSO at
5 mM concentration. UV-visible spectra were recorded for
compounds in order to determine proton dissociation constants
(pKa) in the pH range 2–12 in a 30% (v/v) DMSO/H2O mixture at
25.0  0.1 C. Ionic strength of 0.10 M (KCl) was used in order to
keep the activity coefficients constant. The titrations were per-
formed with carbonate-free KOH solution of known concentration
(0.10 M) with 30% (v/v) DMSO content. The electrode system was
calibrated to the pH¼ log[H+] scale by means of blank titrations
(HCl vs. KOH) according to the method suggested by Irving et al.48
The average water ionization constant (pKw) is 14.52  0.05 in the
30% (v/v) DMSO/H2O mixture. Argon was always passed over the
solutions during the titrations. An Agilent Cary 8454 diode array
spectrophotometer was used to record the UV-visible spectra at an
interval of 200–800 nm. The path length was 2 or 5 cm. Spectro-
photometric titrations were performed on samples containing the
compounds at 10 or 50 mM concentration. Proton dissociation
constants (Ka) of the compounds and the UV-visible spectra of the
individual species in the differently protonated forms were
calculated by the computer program PSEQUAD.49
Cell culture
All the cell lines were purchased from ATCC. MCF-7, DU145 and
PC-3 cells were maintained in RPMI-1640 (LONZA) complete© 2021 The Author(s). Published by the Royal Society of Chemistry
Paper RSC Advancesmedium (10% FBS, 2 mM glutamine and penicillin–strepto-
mycin) at 37 C and 5% CO2. HeLa and MRC-5 cells were
maintained in EMEM (LONZA) complete medium at 37 C and
5% CO2. Treatments were applied in cell specic complete
medium described above.
MTT cytotoxicity assay
Each synthesized compound was dissolved in cell culture grade
DMSO (Sigma) to a nal concentration of 10 mM. Cytotoxicity of
these compounds on cancerous (MCF-7, HeLa, DU145, PC-3)
and non-cancerous (MRC-5) cell lines was tested using MTT
cell viability assay. Briey, in a 96-well plate cells were seeded at
5000 cells per well density, and were le to grow overnight in 5%
CO2 atmosphere at 37 C. Cells were incubated for 72 hours at
37 C under 5% CO2 with each synthesized compound sepa-
rately in 1.5 mM concentration upon the primary screen and
only with the selected compounds in concentrations 0.5, 1, 1.5,
2 and 2.5 mM for IC50 determination. At the end of treatment,
cell viability was measured by MTT assay as described previ-
ously.19 The positive control cisplatin was applied for 24 h in 20,
40, 80, 160, and 330 mM concentrations. Final results were ob-
tained by three independent replicates. GraphPad Prism 7
soware was used to perform statistics and to construct the heat
map.
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37 I. Bacsa, D. Szemerédi, J. Wöling, G. Schneider, L. Fekete
and E. Mernyák, Beilstein J. Org. Chem., 2018, 14, 998.
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B. E. Herman, M. Szécsi and E. Mernyák, Steroids, 2015,
104, 230–236.
39 A. V. Joshi, M. Baidoosi, S. Mukhopadhyay and Y. Sasson,
Org. Process Res. Dev., 2003, 7, 95–97.13896 | RSC Adv., 2021, 11, 13885–1389640 Y. A. Mostafa, B. Kralt, P. P. N. Rao and S. D. Taylor, Bioorg.
Med. Chem., 2015, 23, 5681–5692.
41 N. Al Soom and T. Thieman, Int. J. Org Chem., 2016, 6, 1–11.
42 S. I. El-Hout, S. M. El-Sheikh, H. M. A. Hassan, F. A. Harraz,
I. A. Ibrahim and E. A. El-Sharkawy, Appl. Catal., A, 2015, 503,
176–185.
43 S. C. Mitchell, P. Carmichael and R. Waring, Kirk-Othmer
Encyclopedia of Chemical Technology, ed. 2003.
44 J. Kaizer, R. Csonka and G. Speier, J. Mol. Catal., 2002, 180,
91–96.
45 A. Vaidyan and P. Bhattacharya, Indian J. Chem., 1994, 33,
103–1007.
46 R. U. Janicke, Breast Cancer Res. Treat., 2009, 117, 219–221.
47 A. G. Porter and R. U. Jänicke, Cell Death Differ., 1999, 6, 99–
104.
48 H. M. Irving, M. G. Miles and L. D. Petit, Anal. Chim. Acta,
1967, 38, 475–488.
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